Cosette Pharmaceuticals Secures FDA Approval for First Generic CIPRO®HC with 180 Days Exclusivity
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 16 2025
0mins
Source: Newsfilter
- Market Exclusivity: Cosette Pharmaceuticals has received FDA approval for the first generic version of CIPRO®HC, granting 180 days of Competitive Generic Therapy exclusivity, which is expected to significantly enhance the company's market share in the otic drug sector.
- Commercial Shipment Initiation: The company has commenced commercial shipments, marking the market launch of the generic, which is anticipated to provide patients with a more affordable treatment option for acute otitis externa, addressing the demand for cost-effective medications.
- Showcasing R&D Capabilities: This marks Cosette's fourth Competitive Generic Therapy approval in the last three years, demonstrating its strong R&D and operational capabilities, further solidifying its position in the pharmaceutical industry.
- Sales Potential: According to IQVIA, annual U.S. sales of CIPRO®HC were approximately $17.9 million, and the launch of this generic is expected to generate substantial revenue growth for the company while improving treatment options for patients.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on HLNE
Wall Street analysts forecast HLNE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HLNE is 166.67 USD with a low forecast of 154.00 USD and a high forecast of 181.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 148.640
Low
154.00
Averages
166.67
High
181.00
Current: 148.640
Low
154.00
Averages
166.67
High
181.00
About HLNE
Hamilton Lane Incorporated is a private markets investment company providing solutions to institutional and private wealth investors around the world. The Company offers a variety of investment solutions to address its clients’ needs across a range of private markets, including private equity, private credit, real estate, infrastructure, real assets, growth equity, venture capital and impact. These solutions are constructed from a range of investment types, including primary investments in funds managed by third-party managers, direct investments alongside such funds and acquisitions of secondary stakes in such funds, with a number of its clients utilizing multiple investment types. These solutions are offered in a variety of formats, covering some or all phases of private markets investment programs, which include customized separate accounts, specialized funds, advisory services, distribution management, and reporting, monitoring, data and analytics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BlackRock, Morgan Stanley, and Partners Group Collaborate on New Alternative Investment Product
- New Investment Option: Advisors can now offer clients a diversified set of separately managed accounts for alternative investments.
- Partnership: The new investment option is a collaboration between BlackRock and Partners Group, focusing on private equity, private credit, and real assets.
Continue Reading
Investors Are Drawn to Private Markets, Benefiting Asset Managers.
- Focus on Private Markets: Financial advisors are planning to increase their engagement with private markets for their clients this year.
- Venture and Growth Capital: There is a particular emphasis on venture and growth capital strategies as part of this deeper dive into private markets.
Continue Reading